×
RAPS Learning Portal will be under maintenance on 12 June 2026 between 10 PM - 12 AM ET. Learning Portal functionality and profile access may be unavailable during this window.
We apologize for any inconvenience caused during this time.
  1. You are here:
  2. Homepage
  3. News & Insights Search
  4. New Guidance on Conflict of Interest Disclosures for Advisory Committees

rf-fullcolor.png

 

Regulatory News
8 March 2012
by Alexander Gaffney, RAC

New Guidance on Conflict of Interest Disclosures for Advisory Committees

The US Food and Drug Administration (FDA) released new draft guidance on 8 March about the availability of conflict of interest information and waiver information for members of advisory committees.

The guidance also establishes a procedure for disclosing financial interest and granting conflict-of-interest (COI) waivers to special Government employees (SGEs) and regular employees. The guidance also provides a standardized mechanism for public disclosure of such documents.


Read more:

FDA - Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers

Federal Register - Guidance for the Public, Advisory Committee Members, and Staff; Availability: Advisory Committee Members' Financial Interest Information and Waivers

Return to listing